{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:30:09Z","timestamp":1778643009969,"version":"3.51.4"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In this work, we evaluated recombinant receptor binding domain (RBD)-based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus alum, AddaS03, AddaVax, or the combination of alum and U-Omp19: a novel <jats:italic>Brucella<\/jats:italic> spp. protease inhibitor vaccine adjuvant. Results show that the vaccine formulation composed of U-Omp19 and alum as adjuvants has a better performance: it significantly increased mucosal and systemic neutralizing antibodies in comparison to antigen plus alum, AddaVax, or AddaS03. Antibodies induced with the formulation containing U-Omp19 and alum not only increased their neutralization capacity against the ancestral virus but also cross-neutralized alpha, lambda, and gamma variants with similar potency. Furthermore, the addition of U-Omp19 to alum vaccine formulation increased the frequency of RBD-specific geminal center B cells and plasmablasts. Additionally, U-Omp19+alum formulation induced RBD-specific Th1 and CD8<jats:sup>+<\/jats:sup> T-cell responses in spleens and lungs. Finally, this vaccine formulation conferred protection against an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenge of K18-hACE2 mice.<\/jats:p>","DOI":"10.3389\/fimmu.2022.844837","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T07:54:33Z","timestamp":1646034873000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice"],"prefix":"10.3389","volume":"13","author":[{"given":"Lorena M.","family":"Coria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas M.","family":"Saposnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celeste","family":"Pueblas Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana F.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula S.","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Darriba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia B.","family":"Chemes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julieta","family":"Alcain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Mazzitelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Varese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melina","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J.","family":"Auguste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego E.","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina A.","family":"Pasquevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Cassataro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2102017","article-title":"Neutralizing Activity of BNT162b2-Elicited Serum","volume":"384","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/nejmoa2114583","article-title":"Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine Over 6 Months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 Variants, Spike Mutations and Immune Escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2113468","article-title":"SARS-CoV-2 Neutralization With BNT162b2 Vaccine Dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n296","article-title":"Covid-19: Novavax Vaccine Efficacy is 86% Against UK Variant and 60% Against South African Variant","volume":"372","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1901545","article-title":"SARS\u2212CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-Cell Immunity in Mice","volume":"17","author":"Pollet","year":"2021","journal-title":"Hum Vaccines Immunother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional Assessment of Cell Entry and Receptor Usage for SARS-CoV-2 and Other Lineage B Betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat Microbiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral Targets for Vaccines Against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.126","article-title":"Roadmap to Developing a Recombinant Coronavirus S Protein Receptor-Binding Domain Vaccine for Severe Acute Respiratory Syndrome","volume":"11","author":"Jiang","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.1c00272","article-title":"SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies","volume":"16","author":"Valdes-Balbin","year":"2021","journal-title":"ACS Chem Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing Antibody Levels are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for Antibody as a Protective Correlate for COVID-19 Vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, With Potent Protection Against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging Concepts in the Science of Vaccine Adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016203","article-title":"An Oral Vaccine Based on U-Omp19 Induces Protection Against B. Abortus Mucosal Challenge by Inducing an Adaptive IL-17 Immune Response in Mice","volume":"6","author":"Pasquevich","year":"2011","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jconrel.2015.10.011","article-title":"A Bacterial Protease Inhibitor Protects Antigens Delivered in Oral Vaccines From Digestion While Triggering Specific Mucosal Immune Responses","volume":"220","author":"Ibanez","year":"2015","journal-title":"J Control Release"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.12.012","article-title":"Brucella Abortus Omp19 Recombinant Protein Subcutaneously Co-Delivered With an Antigen Enhances Antigen-Specific T Helper 1 Memory Responses and Induces Protection Against Parasite Challenge","volume":"34","author":"Coria","year":"2016","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00171","article-title":"U-Omp19 From Brucella Abortus Is a Useful Adjuvant for Vaccine Formulations Against Salmonella Infection in Mice","volume":"8","author":"Risso","year":"2017","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.10.006","article-title":"The Trypanosoma Cruzi TcTASV-C Protein Subfamily Administrated With U-Omp19 Promotes a Protective Response Against a Lethal Challenge in Mice","volume":"38","author":"Caeiro","year":"2020","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.05.010","article-title":"SARS-CoV-2 Human T Cell Epitopes: Adaptive Immune Response Against COVID-19","volume":"29","author":"Grifoni","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22267","article-title":"Acceptable Levels of Endotoxin in Vaccine Formulations During Preclinical Research","volume":"100","author":"Brito","year":"2011","journal-title":"J Pharm Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA Dominates the Early Neutralizing Antibody Response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1101\/2021.06.28.21259673","article-title":"Infectivity and Immune Escape of the New Sars-Cov-2 Variant of Interest Lambda","volume-title":"medRxiv","author":"Acevedo","year":"2021"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00183-5","article-title":"Resurgence of COVID-19 in Manaus, Brazil, Despite High Seroprevalence","volume":"397","author":"Sabino","year":"2021","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T Cells Contribute to Survival in Patients With COVID-19 and Hematologic Cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA Vaccines Induce Persistent Human Germinal Centre Responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 Infection of Human ACE2-Transgenic Mice Causes Severe Lung Inflammation and Impaired Function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","article-title":"Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2","volume":"182","author":"Jiang","year":"2020","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 Vaccines Strategies: A Comprehensive Review of Phase 3 Candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008548","article-title":"Developing a Low-Cost and Accessible COVID-19 Vaccine for Global Health","volume":"14","author":"Hotez","year":"2020","journal-title":"PloS Negl Trop Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41421-021-00331-9","article-title":"Distinct BCR Repertoires Elicited by SARS-CoV-2 RBD and S Vaccinations in Mice","volume":"7","author":"Tian","year":"2021","journal-title":"Cell Discov"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi9915","article-title":"Antibodies Elicited by mRNA-1273 Vaccination Bind More Broadly to the Receptor Binding Domain Than Do Those From SARS-CoV-2 Infection","volume":"13","author":"Greaney","year":"2021","journal-title":"Sci Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02991","article-title":"Viral-Induced Enhanced Disease Illness","volume":"9","author":"Smatti","year":"2018","journal-title":"Front Microbiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1016\/j.cell.2021.05.032","article-title":"An Infectivity-Enhancing Site on the SARS-CoV-2 Spike Protein Targeted by Antibodies","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.081","article-title":"SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralizing Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1","volume":"39","author":"Law","year":"2021","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2599-8","article-title":"A Vaccine Targeting the RBD of the S Protein of SARS-CoV-2 Induces Protective Immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e2106845118","DOI":"10.1073\/pnas.2106845118","article-title":"Engineered SARS-CoV-2 Receptor Binding Domain Improves Manufacturability in Yeast and Immunogenicity in Mice","volume":"118","author":"Dalvie","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41421-021-00315-9","article-title":"Yeast-Produced RBD-Based Recombinant Protein Vaccines Elicit Broadly Neutralizing Antibodies and Durable Protective Immunity Against SARS-CoV-2 Infection","volume":"7","author":"Zang","year":"2021","journal-title":"Cell Discov"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9070744","article-title":"Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate With Different Adjuvant Formulations","volume":"9","author":"Siriwattananon","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1038\/s41467-021-23942-y","article-title":"SARS-CoV-2 RBD Trimer Protein Adjuvanted With Alum-3M-052 Protects From SARS-CoV-2 Infection and Immune Pathology in the Lung","volume":"12","author":"Routhu","year":"2021","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.14171","article-title":"Single-Dose Immunisation With a Multimerised SARS-CoV-2 Receptor Binding Domain (RBD) Induces an Enhanced and Protective Response in Mice","volume":"595","author":"Salzer","year":"2021","journal-title":"FEBS Lett"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.20.444848","article-title":"Alum:CpG Adjuvant Enables SARS-CoV-2 RBD-Induced Protection in Aged Mice and Synergistic Activation of Human Elder Type 1 Immunity","author":"Nanishi","year":"2021","journal-title":"bioRxiv"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10253","article-title":"Potent Neutralization of SARS-CoV-2 Including Variants of Concern by Vaccines Presenting the Receptor-Binding Domain Multivalently From Nanoscaffolds","volume":"6","author":"Halfmann","year":"2021","journal-title":"Bioeng Transl Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41421-021-00320-y","article-title":"RBD-Homodimer, a COVID-19 Subunit Vaccine Candidate, Elicits Immunogenicity and Protection in Rodents and Nonhuman Primates","volume":"7","author":"Pan","year":"2021","journal-title":"Cell Discov"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/s41467-021-21665-8","article-title":"Immunogenicity of Prime-Boost Protein Subunit Vaccine Strategies Against SARS-CoV-2 in Mice and Macaques","volume":"12","author":"Tan","year":"2021","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100252","article-title":"SARS-CoV-2 Protein Subunit Vaccination of Mice and Rhesus Macaques Elicits Potent and Durable Neutralizing Antibody Responses","volume":"2","author":"Mandolesi","year":"2021","journal-title":"Cell Rep Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641447","article-title":"Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model","volume":"12","author":"Shrivastava","year":"2021","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102435118","article-title":"Inhibition of Elastase Enhances the Adjuvanticity of Alum and Promotes Anti-SARS-CoV-2 Systemic and Mucosal Immunity","volume":"118","author":"Kim","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B56","doi-asserted-by":"publisher","first-page":"eabf1555","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 Neutralization by Dimeric IgA","volume":"13","author":"Wang","year":"2021","journal-title":"Sci Transl Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 Variants B.1.351 and P.1 Escape From Neutralizing Antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2103022","article-title":"Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization","volume":"384","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a Subunit COVID-19 Vaccine to Induce Protective Immunity","volume":"594","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.10.008","article-title":"From Vaccines to Memory\u00a0and Back","volume":"33","author":"Sallusto","year":"2010","journal-title":"Immunity"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated With Neutralizing Antibody Generation","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501188","article-title":"A Brucella Spp. Protease Inhibitor Limits Antigen Lysosomal Proteolysis, Increases Cross-Presentation, and Enhances CD8+ T Cell Responses","volume":"196","author":"Coria","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1923341","article-title":"A Novel Oral Rabies Vaccine Enhances the Immunogenicity Through Increasing Dendritic Cells Activation and Germinal Center Formation by Expressing U-OMP19 in a Mouse Model","volume":"10","author":"Zhao","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.14348\/molcells.2021.0079","article-title":"Phenotypes and Functions of SARS-CoV-2-Reactive T Cells","volume":"44","author":"Jung","year":"2021","journal-title":"Mol Cells"},{"key":"B65","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A Universal Design of Betacoronavirus Vaccines Against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1159\/000509368","article-title":"Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association With COVID-19 Vaccination and Infection","volume":"181","author":"Simon","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00531-8","article-title":"Interferon-Armed RBD Dimer Enhances the Immunogenicity of RBD for Sterilizing Immunity Against SARS-CoV-2","volume":"31","author":"Sun","year":"2021","journal-title":"Cell Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and its Immune Cross-Reactivity With SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.844837\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T07:54:37Z","timestamp":1646034877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.844837\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":68,"alternative-id":["10.3389\/fimmu.2022.844837"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.844837","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"article-number":"844837"}}